Management of good risk germ-cell tumours

BJU International

Volumn 104, Issue 9 B, 2009, Pages 1387-1391

  Troost, Monique M ^a   Sternberg, Cora N ^b   De Wit, Ronald ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b SAN CAMILLO FORLANINI HOSPITAL   (Italy)

Author keywords

Bleomycin; Chemotherapy; Cisplatin; Dose; Etoposide; Germ cell cancer; Morbidity

Indexed keywords

BLEOMYCIN; CARBOPLATIN; CISPLATIN; ETOPOSIDE;

ALLERGIC PNEUMONITIS; ANEMIA; ANGINA PECTORIS; BLEEDING; BONE MARROW DEPRESSION; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CHILL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FEVER; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; GERM CELL TUMOR; HEART INFARCTION; HUMAN; LEUKEMIA; MORBIDITY; MORTALITY; MULTIPLE CYCLE TREATMENT; NEPHROTOXICITY; NEUROPATHY; NEUROTOXICITY; OTOTOXICITY; OXYGEN THERAPY; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RAYNAUD PHENOMENON; REVIEW; SKIN TOXICITY; SOLID TUMOR; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT; VOMITING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CARBOPLATIN; CISPLATIN; CLINICAL TRIALS AS TOPIC; ETOPOSIDE; HUMANS; IFOSFAMIDE; MALE; NEOPLASMS, GERM CELL AND EMBRYONAL; PROGNOSIS; RISK FACTORS; TESTICULAR NEOPLASMS;

EID: 70350447127     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2009.08864.x     Document Type: Review

References (22)

1. Einhorn LH, Donohue JP. Cis-diamminechloroplatinum, vinblastine and bleomycin combination chemotherapy in disseminated testicular cancer. Ann Intern Med 1977 87 : 293 298
2. Williams SD, Birch R, Einhorn LH et al. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med 1987 316 : 1435 1440
3. de Wit R. Treatment of disseminated non-seminomatous testicular cancer: the European experience. Semin Surg Oncol 1999 17 : 250 256
4. International Germ Cell Cancer Collaborative Group. International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol 1997 15 : 594 603
5. Einhorn LH, Williams SD, Loehrer PJ et al. Evaluation of optimal duration of chemotherapy in favorable-prognosis disseminated germ cell tumors: a Southeastern Cancer Study Group protocol. J Clin Oncol 1989 7 : 387 391
6. Saxman SB, Finch D, Gonin R et al. Long-term follow-up of a phase III study of three versus four cycles of bleomycin, etoposide, and cisplatin in favorable-prognosis germ-cell tumors: the Indiana University experience. J Clin Oncol 1998 16 : 702 706
7. De Wit R, Stoter G, Kaye SB et al. Importance of bleomycin in combination chemotherapy for good-prognosis testicular non-seminoma: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group. J Clin Oncol 1997 15 : 1837 1843
8. De Wit R, Roberts JT, Wilkinson PM et al. Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of 3- or 5-day schedule in good-prognosis germ cell cancer: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council. J Clin Oncol 2001 19 : 1629 1640
9. Sleijfer S. Bleomycin-induced pneumonitis. Chest 2001 120 : 617 624
10. Levi JA, Raghavan D, Harvey V et al. The importance of bleomycin in combination chemotherapy for good-prognosis germ cell carcinoma. Australian Germ Cell Trial Group. J Clin Oncol 1993 11 : 1300 1305
11. Loehrer PJ, Johnson D, Elson P et al. Importance of bleomycin in favorable-prognosis disseminated germ cell tumors: an Eastern Cooperative Oncology Group trial. J Clin Oncol 1995 13 : 470 476
12. Bajorin DF, Sarosdy MF, Pfister DG et al. Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: a multiinstitutional study. J Clin Oncol 1993 11 : 598 606
13. Horwich A, Sleijfer DT, Fosså SD et al. Randomized trial of bleomycin, etoposide, cisplatin compared with bleomycin, etoposide, carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial. J Clin Oncol 1997 15 : 1844 1852
14. Kondagunta GV, Bacik J, Bajorin D et al. Etoposide and cisplatin chemotherapy for metastatic good-risk germ cell tumors. J Clin Oncol 2006 24 : 2597 2598
15. Culine S, Kerbrat P, Kramar A et al. Refining the optimal chemotherapy regimen for good-risk metastatic noseminomatous germ-cell tumors: a randomized trial of the Genito-Urinary Group of the French Federation of Cancer Centers (GETUG T93 BP). Ann Oncol 2007 18 : 917 924
16. De Wit R. Refining the optimal chemotherapy regimen in good prognosis germ cell cancer. Interpretation of the current body of knowledge. J Clin Oncol 2007 25 : 4346 4349
17. O'Sullivan JM, Huddart RA, Norman AR et al. Predicting the risk of bleomycin lung toxicity in patients with germ-cell tumours. Ann Oncol 2003 14 : 91 6
18. Donat SM, Levy DA. Bleomycin associated toxicity: is perioperative oxygen restriction necessary? J Urol 1998 160 : 1347 1352
19. De Wit R, Sleijfer S, Kaye S et al. Bleomycin and scuba diving: where is the harm? Lancet Oncol 2007 8 : 954 955
20. Travis LB, Fossa SD, Schonfeld SJ et al. Second cancers among 40576 testicular cancer patients: focus on long-term survivors. J Natl Cancer Inst 2005 97 : 1354 1365
21. Van den Belt-Dusebout A, de Wit R, Gietema J et al. Treatment-specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol 2007 25 : 4370 4378
22. Van den Belt-Dusebout A, Nuver J, de Wit R et al. Long-term risk of cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol 2006 24 : 467 475